Eagle Pharmaceuticals to Present at Upcoming June Conferences

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)-- Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (NASDAQ: EGRX) today announced that Scott Tarriff, President and Chief Executive Officer, and David Riggs, Chief Financial Officer, will present at two upcoming conferences as follows:

At the Jefferies 2016 Healthcare Conference, Eagle’s presentation is scheduled as follows:

					Date:			June 8, 2016
					Time:			2:00 p.m. Eastern Time
					Webcast:			http://wsw.com/webcast/jeff97/egrx

At the William Blair 36th Annual Growth Stock Conference, Eagle’s presentation is scheduled as follows:

					Date:			June 16, 2016
					Time:			12:20 p.m. Eastern Time/11:20 a.m. Central Time
					Location:			Four Seasons, Chicago
					Webcast:			http://wsw.com/webcast/blair51/egrx

The presentations will be webcast live at the aforementioned times, and archived for 90 days thereafter, via the Company’s website at www.eagleus.com, under the Investors Section.

About Eagle Pharmaceuticals, Inc.

Eagle is a specialty pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products. Eagle’s strategy is to utilize the FDA's 505(b)(2) regulatory pathway. Additional information is available on the company’s website at www.eagleus.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160531005507/en/

Investor Relations for Eagle Pharmaceuticals, Inc.
In-Site Communications
Lisa Wilson, 212-452-2793

Source: Eagle Pharmaceuticals, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• William Blair Downgrades Enovix Corporation (ENVX) to Market Perform
• Salt Lake City Facial Plastic Surgeon Dr. Eric Cerrati Closes Practice for Team Service Day at Ronald McDonald House
• Pinnacle Business Systems Announces Leadership Transition as Rob Anderson Retires After 27 Years; David Traxler Named CEO